Physician profile
Bingyan Wang
NPI 1306263819
$2,248.53
in general payments reported to CMS, 2019-2025
29 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $203 · 2023: $1,095 · 2024: $726 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $487.50 | 2022-2025 | Rinvoq, Qulipta, Ubrelvy |
| Lilly USA, LLC | $222.81 | 2022-2024 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $176.09 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $161.83 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $145.38 | 2023-2025 | |
| Amgen INC. | $136.70 | 2022-2025 | Krystexxa, Repatha, Repatha |
| Xeris Pharmaceuticals, INC. | $129.24 | 2023-2024 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $98.07 | 2023-2025 | Airsupra, Farxiga |
| Dexcom, INC. | $96.58 | 2023-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $71.49 | 2022-2023 | Korlym |
| Amarin Pharma, INC. | $52.69 | 2022-2023 | |
| Horizon Therapeutics Plc | $40.30 | 2023 | Krystexxa |
| Tandem Diabetes Care, INC. | $38.89 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $36.24 | 2023 | Crysvita |
| Glaxosmithkline, LLC. | $36.17 | 2023 | Trelegy Ellipta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.50 | 2023-2024 | |
| Pulmonx Corporation | $30.89 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Otsuka America Pharmaceutical, INC. | $25.93 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $25.33 | 2023 | |
| Almatica Pharma LLC | $24.66 | 2023 | Loreev Xr |
| Halozyme INC | $24.55 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.25 | 2022 | |
| Inspire Medical Systems, INC. | $21.41 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.35 | 2024 | Jardiance |
| Dermavant Sciences, INC. | $20.94 | 2024 | Vtama |
| Ucb, INC. | $19.54 | 2023 | Cimzia |
| Astellas Pharma US INC | $17.57 | 2024 | Veozah |
| Ibsa Pharma INC. | $14.91 | 2024 | Tirosint, Licart |
| Janssen Biotech, INC. | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bingyan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.